Sun Pharmaceutical Industries’ one of the wholly owned subsidiaries has increased its shareholding in Ranbaxy Malaysia, Malaysia, by way of further purchase of 386,865 shares of face value of MYR 1.00 each (equivalent to 4.84%) of Ranbaxy Malaysia.
Ranbaxy Malaysia, is a subsidiary of the company, and the total shareholding of Sun Pharmaceutical Industries along with its wholly owned subsidiary is 85.90%, prior to this purchase of shares.
Post completion of this purchase of shares, the total holding of the company along with its wholly owned subsidiary will increase from 85.90% to 90.74% in Ranbaxy Malaysia.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1842.80 |
| Dr. Reddys Lab | 1309.95 |
| Cipla | 1374.15 |
| Zydus Lifesciences | 941.40 |
| Lupin | 2469.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: